Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Theravance Biopharma Inc

TBPH ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: HOLD

Last Close

$17.06

▼ -0.12%

Market Cap $885.73M · Vol 111.72K

Key Metrics

P/E Ratio

16.92

FWD: 10.95

Market Cap

$885.73M

Small Cap

Div Yield

N/A

EPS Growth

+138.53%

YoY

RSI (14)

70.37

Momentum

Beta

0.19

vs Market

52W High

$21.00

18.76% below

52W Low

$13.08

30.43% above

Volume

111.72K

Avg 142.27K

P/B

3.22

Price-to-book

ROE

N/A

Return on equity

Free Float

95.39%

Public shares

Shariah Compliance8 STANDARDS

✗ Theravance Biopharma Inc (TBPH) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TBPH pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.12%

+0.77%

+4.73%

+25.72%

YTD

-8.82%

+22.56%

+72.67%

+96.32%

Financials & Valuation

TTM · Annual

Total Revenue	$107.46M
Net Income	$105.90M
Revenue Growth (YoY)	-20.86%
Gross Margin	100.00%
Operating Margin	-3.35%
Net Profit Margin	98.54%
ROE	N/A
ROA · ROIC	30.78% · 40.31%

P/E Ratio	16.92
Forward P/E (FY1)	10.95
PEG Ratio	0.03
P/S	8.97
P/B	3.22
P/FCF	4.04
EPS Growth	+138.53%
Outstanding Shares	51.92M

Technical Indicators

50-Day SMA	$16.95
200-Day SMA	$17.28
RSI (14)	70.37
Beta	0.19
52-Week High	$21.00
52-Week Low	$13.08

Volume Today	111.72K
Avg Daily Volume (30D)	142.27K
Relative Volume	0.79x
Volatility (10D)	1.51
Volatility (30D)	2.31
Free Float	95.39%

Analyst Consensus

HOLD

Current Price $17.06

Mean Target $17.67

52W Low$13.08 52W High$21.00

Current

Target

$13.08 $21.00

Current Analyst target

+3.56% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG004HK6YY0

ISINKYG8807B1068

CountryCayman Islands

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.21% JNJ Johnson & Johnson -2.22% ABBV Abbvie Inc -2.99% NVS Novartis AG -13.93% NOVN.S Novartis AG -10.89%

Company Profile

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.